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Oral Cobalamin Supplementation in Dogs with Chronic
Enteropathies and Hypocobalaminemia
L. Toresson, J.M. Steiner, J.S. Suchodolski, and T. Spillmann
Background: Cobalamin deﬁciency is commonly associated with chronic enteropathies (CE) in dogs and current treatment
protocols recommend parenteral supplementation. In humans, several studies have reported equal eﬃcacy of oral and par-
enteral cobalamin administration of cobalamin.
Objectives: To retrospectively evaluate whether oral cobalamin supplementation can restore normocobalaminemia in dogs
with CE and hypocobalaminemia.
Animals: Fifty-one client-owned dogs with various signs of CE and hypocobalaminemia.
Material and Methods: Retrospective study based on a computerized database search for dogs treated at Evidensia Spe-
cialist Animal Hospital, Helsingborg, Sweden during January 2012–March 2014. Inclusion criteria were dogs with signs of
CE, an initial serum cobalamin ≤270 ng/L (reference interval: 234–811 ng/L) and oral treatment with cobalamin tablets.
Serum cobalamin for follow-up was analyzed 20–202 days after continuous oral cobalamin supplementation started.
Results: All dogs became normocobalaminemic with oral cobalamin supplementation. The mean increase in serum cobal-
amin concentration after treatment was 794  462 ng/L. Serum cobalamin concentrations were signiﬁcantly higher after sup-
plementation (mean 1017  460 ng/L; P < .0001) than at baseline (mean 223  33 ng/L).
Conclusion and Clinical Importance: Our results suggest that oral cobalamin supplementation is eﬀective in normalizing
serum cobalamin concentrations in dogs with CE. Prospective studies comparing cellular cobalamin status in dogs being trea-
ted with parenteral versus oral cobalamin supplementation are warranted before oral supplementation can be recommended
for routine supplementation.
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Common causes for cobalamin deﬁciency in dogs arechronic enteropathies (CE), exocrine pancreatic
insuﬃciency (EPI) and familial cobalamin deﬁciency
(reported in Chinese Shar Peis, Giant Schnauzers, Bor-
der Collies and Beagles).1–6 Anecdotal reports of short-
bowel syndrome and cobalamin deﬁciency in dogs also
exist, an association that is well documented in
humans.7,8 Cobalamin deﬁciency in dogs is commonly
associated with canine CE with a reported prevalence of
6–73%.9–13 Hypocobalaminemia has also been reported
to be a negative prognostic factor in dogs with CE or
EPI, associated with an increased risk of euthanasia.9,14
Suggested mechanisms of cobalamin deﬁciency in canine
CE are damage to the ileal mucosal receptors for
binding of cobalamin–intrinsic factor (IF) complexes or
bacterial competition for nutrients in small intestinal
dysbiosis resulting in decreased amounts of cobalamin
available for absorption.15 Cobalamin deﬁciency induces
various clinical and metabolic consequences, including
anorexia, weight loss, failure to thrive, central and
peripheral neuropathies, immunodeﬁciency, and intesti-
nal changes including villous atrophy and malabsorp-
tion of other vitamins and nutrients.2,4,16,17
Gastrointestinal processing and absorption of cobal-
amin in mammals are mediated by carrier proteins and
IF, which in dogs is mainly produced by the pancreas.3
The cobalamin-IF complex is absorbed by receptors in
the ileum.18 However, studies in humans using radioac-
tively labeled cobalamin have shown that approximately
1% of free cobalamin was absorbed along the entire
intestine by passive diﬀusion, independently of IF.19
Several studies in humans with hypocobalaminemia sug-
gest that the administration of oral cobalamin might be
as eﬀective as parenteral administration in restoring
serum cobalamin concentrations in patients suﬀering
from pernicious anemia, various gastrointestinal disor-
ders, or for those on a restricted diet (vegetarians and
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vegans).20–23 A Cochrane review from 2009 reached the
same conclusion.24
Oral cobalamin is prescribed to human patients to
avoid the discomfort, inconvenience, and cost of
monthly injections of vitamin B12. In European coun-
tries, oral cobalamin supplementation is widely uti-
lized.19,25,26 Factors inﬂuencing the increase in serum
cobalamin concentration after oral administration in
humans are dose and time.19–21,26–29 A daily oral
intake of 1,000–2,000 lg cyanocobalamin successfully
normalized serum cobalamin in all studies available in
human patients.19–21,23,27 Continuous increases of
serum cobalamin concentrations during oral cobal-
amin treatment have been demonstrated in several
studies.20,21,23,27,28 Current supplementation protocols
for cobalamin in dogs call for repeated parenteral
injections based on pathophysiologic justiﬁcation, clin-
ical empiric experience, and specialist opinion.5,9,15
Currently, studies assessing the eﬀect of oral cobal-
amin supplementation in dogs with CE are lacking.
However, due to reports of successful oral cobalamin
substitution in humans with various gastrointestinal
disorders, one of the authors (L. T.) has started to
use oral supplementation. The purpose of this retro-
spective study was to evaluate whether oral cobalamin




A retrospective study based on the review of medical records of
dogs treated with oral cobalamin at Evidensia Specialist Animal
Hospital, Helsingborg, Sweden, that commenced between January
2012 and March 2014.
Study Population
Client-owned dogs with signs of CE and hypocobalaminemia
treated with oral cobalamin supplementation at standardized doses
were identiﬁed by searching the electronic patient database of the
hospital. The database ﬁelds for treatment and prescription were
searched for the brand name of cobalamin used for either tablets
or injections.a,b All ﬁelds were also searched for the brand name
as free text. No other brand of cobalamin had been prescribed at
the hospital during the last 5 years. All dogs were given oral
cobalamin tablets once daily until the day before the collection of
the follow-up serum sample for cobalamin determination. If a fol-
low-up sample had been collected on more than one occasion from
the same patient, the ﬁrst sample was chosen. Owners were
instructed not to give cobalamin on the day of the blood test and
were asked to withhold food from their dogs for at least 8 hours
prior to sample collection.
Inclusion Criteria
To be included in the study, a documented physical examina-
tion had to be available as well as a dietary and medical history.
As far as possible, extra-intestinal diseases were excluded in all
dogs by a standardized diagnostic work-up including hematology,
serum biochemistry, fecal examination and abdominal ultrasound.
Dogs also had to have either signs compatible with CE or previ-
ously documented CE veriﬁed with intestinal biopsies. All dogs
included had an initial serum cobalamin concentration ≤270 ng/L
(reference 234–811), and a second serum sample for cobalamin
analyses collected after institution of oral cobalamin supplementa-
tion. The cut-oﬀ of 270 ng/L was chosen as this number represents
the lowest 5% of the reference range, and dogs with signs of CE
and serum cobalamin concentrations in the lowest reference range
might have subtle cobalamin deﬁciency, as shown in a recent
study.30 Dogs that had previously been treated with cobalamin
were included if the last cobalamin treatment was administered at
the latest 30 days before a serum cobalamin of ≤270 ng/L was
determined. All dogs included had been treated with oral
cyanocobalamin tabletsa (1 mg). Dogs with a body weight of 1–
10 kg received ¼ tablet, dogs with a body weight of >10–20 kg
received ½ tablet, and dogs with a body weight >20 kg received 1
tablet daily.
Exclusion Criteria
Dogs were excluded if they received any form of cobalamin
supplementation at the time of diagnosing hypocobalaminemia
or if parenteral cobalamin supplementation had been adminis-
tered in parallel with oral treatment. Dogs were also excluded
when there was documented failure to comply with the pre-
scribed dose of cobalamin, or if medical records were incom-
plete or contained too little data for retrospective calculation of
the canine inﬂammatory bowel disease activity index (CIB-
DAI).31
Cobalamin Analysis
Serum samples were refrigerated within 2 hours of collection,
sent with refrigerated transport and analyzed within 1–4 days. It
has been shown previously that cobalamin is stable during these
storage conditions.32 Serum cobalamin concentrations were deter-
mined before and after oral cobalamin treatment. Increases in
serum cobalamin concentrations after supplementation were fur-
ther stratiﬁed based on initial serum cobalamin concentrations and
CIBDAI at inclusion. Increases in serum cobalamin concentrations
were also compared between dogs that had a change in diet or
medical treatment during supplementation and dogs that had an
unaltered diet and treatment. The cobalamin analyses were per-
formed at IDEXX VetMedLabor, Ludwigsburg, Germany using
an automated chemiluminescence immunoassay.c Serum samples
were sent by refrigerated transport.
Baseline Data
The following data were obtained from case records: breed,
sex, age, body weight and body condition score (BCS) at time of
diagnosis. Further, medication history, diet, clinical signs, and
physical examination at time of diagnosis and at follow-up were
noted. CIBDAI was calculated retrospectively for the time when
hypocobalaminemia was diagnosed based on information from
the medical records. For dogs that were already receiving
immunosuppressive therapies at study inclusion, CIBDAI was
also retrospectively calculated for the time-point before these
dogs had undergone endoscopy and before immunosuppressive
treatment being commenced. Other laboratory parameters avail-
able for some of the patients included folate, serum trypsin-like
immunoreactivity (TLI), canine pancreatic lipase immunoreactiv-
ity (c-PLi, as measured by Spec-cPL) or SNAP canine pancreatic
lipase (SNAP-cPL), and histopathologic reports from gastroin-
testinal biopsies. All biopsies were analyzed by board certiﬁed
pathologists at the veterinary pathology laboratory Biovet in
Sollentuna, Sweden.
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Statistical Analyses
The D’Agostino & Pearson omnibus normality test was used
for normality testing. Serum cobalamin concentrations before and
after cobalamin supplementation were analyzed with a paired t-
test. CIBDAI in dogs receiving immunosuppressive treatment was
compared to that in dogs not receiving immunosuppressive treat-
ment using a Mann–Whitney test. CIBDAI was also compared at
the time of initiation of immunosuppressive treatment to that at
the time of study inclusion using a Wilcoxon matched-paired
signed rank test. Increases in serum cobalamin concentrations
stratiﬁed after initial serum cobalamin concentrations were ana-
lyzed with an unpaired t-test. Comparison of increases in serum
cobalamin concentration based on CIBDAI at inclusion were ana-
lyzed with ordinary one-way ANOVA. An unpaired t-test was
used for the statistical analysis of increases in serum cobalamin
concentrations in patients with an unaltered treatment plan com-
pared to patients that underwent changes in diet or medical treat-
ment during supplementation. All statistical analyses were
performed using a commercially available software package.d
Results
Baseline Characteristics
Fifty-one dogs met the inclusion criteria, of which 34
were males (67%; 26 intact and 8 neutered males) and
17 were females (33%; 15 intact and 2 spayed females).
Thirty diﬀerent breeds were represented, including
mixed breed dogs (7/51; 14%), followed by German
Shepherd (3), Labrador Retriever (3), Soft Coated
Wheaten Terrier (3), Cavalier King Charles Spaniel (3),
and Miniature poodle (3). Of the remaining 29 dogs,
there were 2 Giant Schnauzers present, a breed for
which familial cobalamin deﬁciency has been reported.2
No other breeds for which familial cobalamin deﬁciency
has been reported were noted.
All dogs were older than 1 year of age, ranging from
1.3 to 12.8 years (median 4.9). Body weights ranged
from 2.6 to 52.0 kg (median 14.0) at the time of diagno-
sis and BCSs ranged from 2–7/9 (median 5/9).
Medication History and Diet
Twenty-two of the 51 dogs were receiving immuno-
suppressive treatment at the time of study inclusion
when hypocobalaminaemia was documented (Table 1).
Median duration of immunosuppressive treatment was
566 days (range 9–2,811 days) before study inclusion.
Miscellaneous treatments in this group consisted of
olsalazin (6), metoclopramide (3), folate (2), or metron-
idazole (1).
The remaining 29 dogs were not treated with
immunosuppressive drugs when hypocobalaminemia
was diagnosed. However, 4 dogs had received miscella-
neous treatments for gastrointestinal disease, such as
folate (2), sucralfate (1), and pancreatic enzymes (1). Of
those 29 dogs, 8 were started on immunosuppressive
drugs during oral cobalamin supplementation. Six of
those 8 dogs had endoscopically collected biopsies con-
ﬁrming chronic gastrointestinal inﬂammation. CE was
also suspected in the remaining 2 dogs that were con-
currently diagnosed with chronic pancreatitis, but the
owners declined further work-up. Immunosuppressive
treatment was hence started without endoscopy in those
dogs and led to clinical improvement.
Previous parenteral cobalamin supplementation had
been administered to 12/51 dogs (24%, Table 1). The
supplementation ended 37–1,788 days before study
inclusion. Eight dogs had received parenteral supple-
mentation alone (1 injection/week during 4–6 weeks),
while 4 dogs had received both parenteral and enteral
supplementation concurrently (1–4 injections parallel
with oral treatment during 100–200 days). In all dogs,
recurrence/persistence of hypocobalaminaemia following
withdrawal of cobalamin supplementation had been
documented before study inclusion.
Forty of 51 dogs were fed commercial pet food kib-
bles from a major pet food company, 5 dogs were fed
various commercial raw food diets, 4 dogs received kib-
bles mixed with a home-cooked diet, and 2 dogs were
exclusively fed a home-cooked diet. When the second
serum cobalamin sample was collected, 19/51 dogs were
fed a new diet (Table 1). In total, 26/51 dogs had no
change in medical treatment or diet compared to base-
line at follow-up aside from the addition of oral
cyanocobalamin (20/26) or cyanocobalamin and folate
(6/26).
Historical Findings and CIBDAI
Presenting complaints at time of diagnosis included
anorexia (21), diarrhea (17), lethargy (16), weight loss
(14), vomiting (13), increased frequency of defecation
(9), signs of abdominal pain (6), pica (3), borborygmus
(3), excessive licking of the mouth, paws, or the ﬂoor
(3), halitosis (2), retching (2), melena (2), bad hair coat
Table 1. Selected data and treatment of 51 dogs with
hypocobalaminemia.





Age (years)a 1.3–12.8 (4.9)
CIBDAIa 1–13 (5)
IS txa 22/51
IS tx started before
inclusion (days)
9–2,811 (566)
Previous cbl txa 12/51
Previous cbl tx ended
before inclusion (days)
37–1,788 (146)
Concurrent GI diseasesa Pancreatitis 4c/51, EPI 1/51
IS tx started/changedb 14/51
Diet changeb 19/51
Unaltered diet/txb 26/51
CIBDAI, canine inﬂammatory bowel disease index. IS, immuno-
suppressive; cbl, cobalamin; tx, treatment.
Dogs under immunosuppressive treatment at inclusion were
treated with the following drugs as single treatment or in combina-
tion: Methylprednisolone (10), Prednisolone (10), Azathioprine (3),
Cyclosporine (2) and/or Budosenide (1).
aAt inclusion.
bDuring cobalamimin supplementation.
c1 dog had borderline PLI.
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(1), syncope (1), seizures (1), and polyuria and polydip-
sia (1).
The median CIBDAI for all dogs at study inclusion
was 5 (range 1–13; Table 1). The CIBDAI scores at
inclusion were signiﬁcantly lower (P = .0005) for dogs
receiving immunosuppressive therapies (n = 22;
CIBDAI = 3, range 1–13) compared to the remaining
dogs (n = 29; CIBDAI = 6, range 2–14).
For the 22 dogs already receiving immunosuppressive
treatment at study inclusion, the CIBDAI had progres-
sively improved following initiation of immunosuppres-
sive treatments, and was signiﬁcantly lower (P = .0059)
by the time of study inclusion (CIBDAI = 3, range 1–
13) compared with that calculated retrospectively and
before medical intervention (CIBDAI = 6, range 2–10).
Cobalamin
Mean serum cobalamin concentrations at inclusion
was 223  33 ng/L (reference interval: 234–811). At fol-
low-up 20–202 days (median 72) after initiation of con-
tinuous oral cobalamin supplementation, the mean
serum cobalamin concentration was 1,017  460
(Fig 1). The diﬀerence between serum cobalamin con-
centrations before and after treatment was statistically
signiﬁcant (P < .0001). The mean increase in serum
cobalamin concentration was 794  462 ng/L. The
smallest increase was 73 ng/L. The dog with the small-
est response, a German Shepherd dog sampled 54 days
after start of supplementation, had previously been trea-
ted with parenteral cobalamin supplementation achiev-
ing an equally poor response. This dog was
unfortunately lost to further follow-up. The dogs with
the second and third smallest response had follow-up
blood samples collected at 64 and 76 days, respectively.
Both dogs were continued on oral cobalamin supple-
mentation. At the next follow-up, serum cobalamin
concentrations had continued to increase by 122 and
128% as compared to serum cobalamin concentration
during the ﬁrst follow-up, respectively. Increases in
serum cobalamin concentrations were stratiﬁed based
on serum cobalamin concentrations at time of inclusion
(Fig 2) or CIBDAI at time of inclusion (Fig 3). There
were no statistically signiﬁcant diﬀerences between the
groups (P = .98 and .83, respectively). Furthermore,
there was no statistically signiﬁcant diﬀerence between
the increase in serum cobalamin concentrations between
the dogs that had an unaltered diet or medical treat-
ment during supplementation compared with the dogs
that had a change in diet or medical treatment (P = .27;
Fig 4).
Folate and Pancreatic Function Tests
Serum folate concentrations at time of inclusion
were available for 49 of 51 dogs. Two of these 49 dogs
were treated with oral folate because of previously
diagnosed folate deﬁciency. Of the remaining 47 dogs,
subnormal serum folate concentrations were noted in
20 of 47 dogs (43%), while 7 dogs (15%) had
Fig 1. Serum cobalamin concentrations in 51 dogs with
hypocobalaminemia treated with oral cobalamin supplementation
at baseline and post treatment. Long horizontal line represents
mean; short horizontal line standard deviation.
Fig 2. Increase in serum cobalamin concentrations post supple-
mentation in dogs stratiﬁed after serum cobalamin concentrations
at inclusion (low-normal = 234–270 ng/L; n = 24, subnor-
mal = <234 ng/L; n = 27) Long horizontal line represents mean;
short horizontal line standard deviation.
Fig 3. Increase in serum cobalamin concentrations post supple-
mentation in dogs based on canine inﬂammatory bowel disease
index (CIBDAI) at inclusion (CIBDAI 1–3; n = 18, CIBDAI 4–5;
n = 10, CIBDAI > 6; n = 23). Long horizontal line represents
mean; short horizontal line standard deviation.
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increased levels of serum folate concentrations (refer-
ence interval 9.3–24 ng/mL).
Serum TLI concentrations were available for 31/51
dogs. One dog, a mixed-breed, had a TLI of 1.6 lg/L
consistent with EPI (reference interval 8.5–35 lg/L,
IDEXX VetMed Labor). Of the remaining dogs, 28/30
had serum TLI concentrations within the reference inter-
val while 2/30 had a serum TLI above 50 lg/L. The 2
dogs with increased serum TLI concentrations were fur-
ther tested for pancreatitis by measurement of serum
Spec-cPL concentration or by running a SNAP-cPL test,
which were normal or negative, respectively.
Results for canine pancreatic lipase testing were avail-
able for 22 dogs and a canine SNAP-cPL was available
for 13 dogs. Eighteen of 22 dogs had a cPLI concentra-
tion within the reference interval of 0–200 lg/L, one
mixed-breed dog had a cPLI of 251 lg/L, and 3 dogs (a
Miniature Poodle and 2 Cavalier King Charles
Spaniels) had cPLI concentrations above 400 lg/L.
Histopathology
Histopathology reports from gastrointestinal biopsies
were available for 33/51 dogs (65%). Biopsies were col-
lected endoscopically in 32 dogs and surgically via
laparotomy in 1 dog. Endoscopic biopsies were
retrieved from the gastric mucosa, duodenum, and
colon in 28/32 dogs and only from the gastric mucosa
and duodenum in 4/32 dogs. Ileal biopsies were avail-
able only from the dog undergoing laparotomy. Lym-
phocytic-plasmacytic inﬂammation was seen in 28 dogs
while 5 dogs had a predominantly eosinophilic inﬂam-
mation of the gastrointestinal tract. The inﬂammation
of the small intestine and colon was characterized as
mild to moderate in all dogs. Evidence for gastrointesti-
nal neoplasia was not found in any of the biopsies.
Discussion
In this study, serum cobalamin concentrations
increased signiﬁcantly and normocobalaminemia was
restored in all dogs with CE and hypocobalaminemia
after daily oral cobalamin supplementation for 20–
202 days. These results suggest that oral cobalamin sup-
plementation might be an alternative to parenteral
administration in dogs with CE and cobalamin deﬁ-
ciency. Daily oral cobalamin supplementation is usually
a cheaper, simpler, and pain-free alternative to weekly
cobalamin injections. Parenteral cobalamin supplemen-
tation has been the only recommended route of cobal-
amin administration in dogs with cobalamin
deﬁciency.5,9,15 Studies validating parenteral supplemen-
tation protocols in dogs are however lacking. Similarly,
to our knowledge, no studies evaluating the eﬃcacy of
oral cobalamin supplementation in dogs with CE and
hypocobalaminemia have been published. This is in
contrast to human medicine where oral supplementation
has already been widely studied in various conditions
associated with cobalamin deﬁciency.19–22,28,29 In
humans, parenteral cobalamin is administered intramus-
cularly or subcutaneously, which has been associated
with adverse eﬀects such as pain and, rarely, adverse
reactions including localized scleroderma or tissue
necrosis.26,33,34 Parenteral cobalamin administration
might have other disadvantages compared to oral sup-
plementation. In some countries, such as Sweden or
Finland, pet owners are not legally allowed to give
injections to their pets aside from insulin and hyposensi-
tization treatment. Parenteral cobalamin injections thus
have to be given by a veterinary health care provider,
increasing inconvenience, time, and costs. Even in coun-
tries where pet owners are allowed to give injections,
not all owners are comfortable performing this task.
Dogs might show pain and some people are very reluc-
tant to handle hypodermic needles and syringes. In this
study, the injectable form of cobalamin was more than
double the price of the oral supplement for a 3-month
treatment period, without the costs for veterinary con-
sultation and injections.
One possible explanation why oral cobalamin might
be eﬀective in restoring normocobalaminemia in dogs
with CE is the possibility of an alternative absorptive
pathway of cobalamin beyond receptor-mediated trans-
port in the ileum, which has been reported in humans.19
This might explain why oral cobalamin supplementation
has been eﬀective in normalizing serum cobalamin con-
centrations as well as serum MMA and homocysteine
concentrations in humans lacking IF or an intact
ileum.19–23,28
Factors known to inﬂuence serum cobalamin con-
centrations in humans treated with oral cobalamin
supplementation are dose and time. When oral cobal-
amin was given to human patients at 500 lg/day, it
produced satisfactory responses in the majority of
patients but caused borderline circulating concentra-
tions in a few patients.19,26,27 A daily oral starting
dose of 1,000–2,000 lg/day is currently recommended
for humans.19–21,24–26 Using this dose, there has been
no statistical diﬀerence between oral and parenteral
supplementation in serum cobalamin concentrations
during and post treatment.20,21,23 The dose used for
dogs in this study was extrapolated from human stud-
Fig 4. Increase in serum cobalamin concentrations post supple-
mentation in dogs with unaltered diet and medical treatment dur-
ing supplementation (n = 26) compared with dogs that had a
change in diet or treatment (n = 25). Long horizontal line repre-
sents mean; short horizontal line standard deviation.
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ies. However, it is possible that some dogs require
higher doses, or that not all dogs in the study
received their daily dose as prescribed. Regarding
increase in serum cobalamin concentration over time,
5 separate studies demonstrate that serum cobalamin
concentrations increase with continuous oral cobal-
amin supplementation in humans.20,21,23,27,28 Serum
cobalamin concentrations were only measured at one
time-point post treatment during our study. Thus, we
cannot evaluate if a continuous oral cobalamin
supplementation in dogs would be associated with
a continuous increase in serum cobalamin concentra-
tion. Further studies are needed to answer this
question.
Another factor potentially inﬂuencing response to
cobalamin supplementation in dogs is breed. Two Giant
Schnauzers were included in our study, a breed in which
familial cobalamin deﬁciency has been reported. These
dogs were 6 and 8.7 years old, respectively, at the time
of inclusion. Both were diagnosed with chronic eosino-
philic enteritis. Histopathology reports and age of onset
in these dogs made familial cobalamin deﬁciency less
likely than cobalamin deﬁciency as a result of CE. No
other breeds known for familial cobalamin deﬁciency
were represented in this study.
As the main source of IF in dogs is the exocrine pan-
creas, exocrine pancreatic function is also likely to inﬂu-
ence the eﬀect of cobalamin absorption.3 However,
exocrine pancreatic function was not assessed in all
dogs. Only 1 dog in our study had conﬁrmed EPI and
CE. This dog responded well to oral cobalamin substi-
tution. Whether all dogs with EPI and cobalamin deﬁ-
ciency would respond to oral cobalamin
supplementation remains to be determined.
Most dogs responded very well to oral cobalamin
supplementation, but some responded less well than
others. When speciﬁcally looking for similarities in the
3 dogs with the smallest response to oral cobalamin
substitution regarding history, dose in mg/kg, diet and
type and degree of intestinal inﬂammation, none could
be identiﬁed. Why some dogs do not respond as satis-
factorily to oral treatment is unknown and requires fur-
ther investigation, as does the optimal dosing regimen
(higher or lower) to restore normocobalaminaemia.
The inclusion criterion for this study was a serum
cobalamin concentration of ≤270 ng/L (reference inter-
val: 234–811 ng/L). The majority of the patients had a
serum cobalamin concentration below the reference
interval, but it might be argued that dogs with a serum
cobalamin concentration between 234 and 270 ng/L
were not truly deﬁcient. However, hypocobalaminemia
can result in severe metabolic consequences and is asso-
ciated with a negative outcome.9,16,17 Thus, rapid identi-
ﬁcation and early intervention is recommended.35
Therefore, some centers recommend starting cobalamin
supplementation when serum cobalamin concentrat-
ion is in the low reference range (see www.vetmed.
tamu.edu/gilab). A recent study assessing MMA in dogs
with diﬀerent levels of serum cobalamin concentrations
demonstrated that 19% of all dogs with serum cobal-
amin concentrations in the lower reference range had
an increased MMA.30 This suggests that some of these
dogs were cobalamin deﬁcient on a cellular level, and
supports the recommendation to start treatment in the
low reference range. It also parallels recommendations
in human medicine, where supplementation often is
started at the lowest end of normal reference interval, if
serum homocysteine and/or MMA concentrations are
concurrently increased.36
This study has several limitations. The time-point for
the follow-up blood sample varied substantially from 20
to 202 days, which might inﬂuence the results as serum
cobalamin levels have been shown to increase over time
with continuous treatment in humans.20,21,23,27,28 The
owners were further instructed not to give cobalamin
tablets on the day of the follow-up blood test, but some
might have forgotten, potentially causing falsely elevated
serum levels. Furthermore, EPI could not be excluded in
20/51 dogs since serum TLI concentrations were not
available. Consequently, more than 1 dog in the study
might have had both CE and EPI. This might inﬂuence
the response to oral cobalamin substitution. Homocys-
teine and MMA were not measured in this study, which
is a prerequisite in many countries to diagnose and treat
cobalamin deﬁciency in humans.37,38 Whether such an
approach would also be favorable for canine patients still
needs to be studied. Despite several study limitations, our
results suggest that oral cobalamin appears eﬀective in
restoring normocobalaminemia in dogs with CE,
although 3 dogs had only a modest increase in their
serum cobalamin concentration in response to oral cobal-
amin treatment. To further evaluate the eﬃcacy of oral
cobalamin supplementation, a randomized prospective
study comparing serum cobalamin and cellular cobal-
amin status in dogs treated with oral or parenteral cobal-
amin supplementation is warranted.
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